Font size

There are two types of activities being undertaken by IMP: projects and continuous activities. For projects separate funding is sought, the continuous activities are financed from the running budget of IMP. All decisions are made by the member organisations of IMP. The execution is the responsibility of the board of IMP.


  • Developing and establishing an IMP worldwide patient registrer: a non-clinical, patient-owned databank of mitochondrial patients all over the world. The goal is to gain more insight, knowledge and understanding of mitochondrial patients. With the explicit permission from the patients the data can be used by researchers to carry out further studies. A designated steering committee within IMP is responsible for the execution of this ambitious project. This steering committee reports back to the board on a regular basis.


  • IMP quality of life study: an international online study on the daily lives of mitochondrial patients was carried out in cooperation with a renowned German psychological research institute. This project was funded by the German DGM, a member of IMP. Results of the pilot in Germany will be published in 2018. The outcomes of this study have already formed the basis for a further QOL study in The Netherlands, focussing on different other aspects and as such adding value. Intervention therapies will be developed so that patients can manage their disease and its implications in their daily life. This study is funded with a huge grant from a Dutch (patient) foundation.


  • Establishing and publishing a list of drugs which are potentially harmful for mitochondrial patients (naturally checked for its medical correctness). This list is a hit on the IMP website and has already proven its value. The list is updated on a regular basis in close cooperation with the Radboud Center for Mitochondrial Medicine in Nijmegen. In 2018 IMP will organise a workshop with a small group of mitochondrial and pharmacological specialists with the goal of improving the list on the basis of the latest scientific insights and empirical experiences. As such the list is empowering patients with good, thorough information.


Continuous activities

Based on the mission and objectives of IMP there are several activities which are carried continuously/regularly:

Management of the Global Mitochondrial Disease Awareness Week, campaign around the world, including the Light Up for Mito initiative.

Build network with researchers and clinicians (attending conferences, personal visits, supporting activities, organising meetings, participating in Euromit).

Organising and facilitating workshops with mitochondrial specialists, researchers, and reps from pharmaceutical industry to discuss important issues in the mitochondrial community, such as consensus on outcome measures for trials on mitochondrial myopathy, or sharing experiences with the FDA (Food and Drugs Administration, US) and EMA (European Medicines Agency), or developing an updated list of potentially harmful drugs for mitochondrial diseases.

Assisting EMA with presentations from patients with specific mitochondrial disorders (MELAS, Leigh, MNGIE), so that the authorities understand the impact of the disease on daily life and as such will understand why developing and approving drugs is so important.

Ongoing support for grant applications regarding studies into mitochondrial disease (active role, responsible for work package, in advisory committee, tactic support). The scientific committee of IMP is advising the board on these requests.

Supporting ITN’s (Innovative Training Networks) funded by the European Commission to train and educate young scientists/academics into mitochondrial medicine, different aspects (MEET in the past, now MORPH-O-FUNCTION).

Participating in patient advocacy groups for ERN’s ( European Reference Networks are virtual networks involving healthcare providers across Europe) through individual IMP representatives. Two ERN’s involve mitochondrial patients: the one for neuromuscular disorders (EURO-NMD) and the one for hereditary metabolic disorders (MetabERN). More info:

Liaison for individual mitochondrial patients all over the world, particularly in countries where there is not a national organisation, including Poland, Brazil, Bulgaria, Pakistan and Algeria. 

Managing a closed community for mitochondrial patients on Facebook. Patients and families from more than 37 countries have joined and share information and experiences.

Supporting national campaigns when needed (national patient information days, providing information in different languages, supporting national information days).

Facilitating bilateral contacts between member organisations, and being a channel of communication and information between members.

Managing the internal organisation of IMP.


IMP is a member of Eurordis, which has international partners such as NORD (National Organisation for Rare Diseases) and CORD. Information on rare diseases and related issues can be found at:

© 2020 Int. Mito Patients